{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000364","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.857420+00:00","generated_at":"2026-06-20T18:49:17.666219+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Athira enters ATM stock offering; reports ~$245.2M cash as of Dec 31, 2022","bullets":["Entered Sales Agreement with Cantor Fitzgerald & BTIG for at-the-market offering of common stock.","Agents to receive 3.0% of gross proceeds; Company has no obligation to sell any shares.","Preliminary cash, equivalents and investments total ~$245.2M as of Dec 31, 2022 (unaudited).","Shares to be issued under effective shelf registration statement on Form S-3 (File No. 333-261073).","Prospectus supplement dated Jan 6, 2023 filed with SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000364","json":"https://secwatch.observer/filing/0000950170-23-000364.json","markdown":"https://secwatch.observer/filing/0000950170-23-000364.md","text":"https://secwatch.observer/filing/0000950170-23-000364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/0000950170-23-000364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/atha-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:49:17.666219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbd8b90078d5c48756a6669a99fd89488208cd4e","claim":"LeonaBio, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and BTIG, LLC valued at maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement (effective 2023-01-06).","evidence_excerpt":"On January 6, 2023, Athira Pharma, Inc, a Delaware corporation (the “Company”), entered into a Controlled Equity Offering Sales Agreement SM (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and BTIG, LLC (“BTIG” and together with Cantor, the “Agents” and each, an “Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/0000950170-23-000364-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co. and BTIG, LLC"},{"label":"Value","value":"maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement"},{"label":"Effective","value":"2023-01-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}